Activation of ChREBP is associated with increased lipogenesis, leading to a marked increase in hepatic steatosis that is known to increase the expression of PPAR-γ [28], a lipogenic factor capable of suppressing SIRT1 expression [16]. Here, MLXIPL is linked to fatty liver disease.